Relabeling the medications we call antidepressants

Area of Science:

• Psychiatry
• Pharmacology
• Clinical Psychology

Background:

• The efficacy and safety of antidepressant medications are subjects of ongoing scientific debate.
• Current labeling and marketing of these drugs may not fully reflect their observed effects and side effect profiles.

Purpose of the Study:

• To critically evaluate whether current antidepressants meet established criteria for true antidepressant efficacy and safety.
• To examine the risk-benefit balance and compare the effect sizes of antidepressant effects versus side effects.

Main Methods:

• Review and analysis of existing clinical trial data and scientific literature on antidepressant medications.
• Comparison of antidepressant effects against placebo, alternative treatments, and reported side effects.

Main Results:

• Antidepressants may not demonstrate clear superiority over placebo across all measures.
• Reported side effects, including sexual dysfunction and increased suicidality, can have larger effect sizes than therapeutic effects.
• The risk-benefit profile may not consistently favor antidepressants over other interventions.

Conclusions:

• The current label "antidepressant" may be scientifically misleading given the data on efficacy and side effects.
• A re-evaluation of drug classification and labeling is warranted to ensure accurate consumer information and informed consent.
• Alternative labels, reflecting the common side effects like antiaphrodisiac effects, might be more scientifically accurate.